{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T10:08:01Z","timestamp":1753870081219,"version":"3.41.2"},"reference-count":43,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CPT Pharmacom &amp; Syst Pharma"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Acetaminophen (APAP), an over\u2010the\u2010counter analgesic and antipyretic, can cause hepatotoxicity when ingested in large overdoses. APAP has multiple formulations including immediate\u2010release (IR) and extended\u2010release (ER) preparations. A recently published consensus statement on the management of APAP poisoning indicated that management of APAP\u2010ER overdose is the same as that for APAP\u2010IR overdose. Consistent with this consensus, it was previously reported that quantitative systems toxicology (QST) modeling using DILIsym predicted similar pharmacokinetic (PK) and hepatic biomarker profiles for the APAP\u2010ER and APAP\u2010IR formulations after overdose in healthy adults. Hepatic injury from APAP is caused by the reactive metabolite, N\u2010acetyl\u2010\u03c1\u2010benzoquinone imine (NAPQI), which is formed predominantly by CYP2E1\u2010mediated metabolism and eliminated by hepatic glutathione. As such, conditions that can increase NAPQI production (e.g., CYP2E1 induction by alcohol) or decrease hepatic glutathione stores (e.g., underling liver disease) may impact PK and susceptibility to hepatotoxicity after overdose of APAP\u2010IR and APAP\u2010ER. In the current study, APAP\u2010IR and APAP\u2010ER models in chronic alcohol users and individuals with low hepatic glutathione were developed and verified within DILIsym. Simulations using verified models predicted similar PK and hepatic biomarker profiles for the APAP\u2010ER and APAP\u2010IR formulations in moderate and excessive chronic alcohol users and adults with low hepatic glutathione levels after single acute overdoses up to ~100\u2009g and repeat supratherapeutic ingestions (up to 7.8\u2009g\/day for 10\u2009days). These results further support that approaches to manage APAP\u2010IR overdoses can be applied to manage APAP\u2010ER overdoses in adults with chronic alcohol consumption or lower hepatic glutathione levels.<\/jats:p>","DOI":"10.1002\/psp4.70045","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:19:15Z","timestamp":1747207155000},"page":"1236-1251","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quantitative Systems Toxicology Modeling of Acetaminophen Pharmacokinetics and Hepatic Biomarkers After Overdoses of Extended\u2010Release and Immediate\u2010Release Formulations in Adults With Chronic Alcohol Use or Low Glutathione"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7009-0944","authenticated-orcid":false,"given":"Kyunghee","family":"Yang","sequence":"first","affiliation":[{"name":"Quantitative Systems Pharmacology Solutions, Simulations Plus Inc.  Research Triangle Park North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6926-8844","authenticated-orcid":false,"given":"James J.","family":"Beaudoin","sequence":"additional","affiliation":[{"name":"Quantitative Systems Pharmacology Solutions, Simulations Plus Inc.  Research Triangle Park North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2815-2084","authenticated-orcid":false,"given":"Brett A.","family":"Howell","sequence":"additional","affiliation":[{"name":"Quantitative Systems Pharmacology Solutions, Simulations Plus Inc.  Research Triangle Park North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Mullin","sequence":"additional","affiliation":[{"name":"Physiologically\u2010Based Pharmacokinetics Solutions, Simulations Plus Inc.  Research Triangle Park North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham","family":"Amini","sequence":"additional","affiliation":[{"name":"Physiologically\u2010Based Pharmacokinetics Solutions, Simulations Plus Inc.  Research Triangle Park North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C. K.","family":"Lai","sequence":"additional","affiliation":[{"name":"Kenvue  Summit New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0663-2709","authenticated-orcid":false,"given":"Cathy K.","family":"Gelotte","sequence":"additional","affiliation":[{"name":"Independent Consultant  Westbrook Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sury","family":"Sista","sequence":"additional","affiliation":[{"name":"Kenvue  Summit New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3831-7910","authenticated-orcid":false,"given":"Evren","family":"Atillasoy","sequence":"additional","affiliation":[{"name":"Kenvue  Summit New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3727\/105221617X15084371374138"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2018.1529320"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.55.6.871"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2017.1339887"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.27739"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13304"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2019.09.003"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-012-9266-0"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2014.02.007"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.192930"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.108"},{"key":"e_1_2_9_13_1","unstructured":"P.Clinical \u201cGuidance for Industry Drug\u2010Induced Liver Injury: Premarketing Clinical Evaluation Guidance for Industry Drug\u2010Induced Liver Injury: Premarketing Clinical Evaluation \u201d2009."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20673"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00223-9"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(94)90524-X"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.29.9.1153"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(88)90544-9"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.106574"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)92150-5"},{"key":"e_1_2_9_21_1","first-page":"898","article-title":"Pharmacokinetics and Metabolism of Acetaminophen in Normal, Alcoholic and Cirrhotic Subjects","volume":"7","author":"Villeneuve J. P.","year":"1983","journal-title":"Gastroent\u00e9rologie Clinique et Biologique"},{"key":"e_1_2_9_22_1","first-page":"513","article-title":"Acetaminophen Metabolism in Recovering Alcoholics","volume":"12","author":"Skinner M. H.","year":"1990","journal-title":"Methods and Findings in Experimental and Clinical Pharmacology"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03368.x"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04364.x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650701447020"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1983.14"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.2174\/157488406776872514"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198207020-00001"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12802"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(86)80139-8"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtbi.2020.110559"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/096032719101000612"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2018.00066"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2008.05.005"},{"key":"e_1_2_9_35_1","first-page":"87","article-title":"A Review of the Evidence Concerning Hepatic Glutathione Depletion and Susceptibility to Hepatotoxicity After Paracetamol Overdose","volume":"3","author":"Kalsi S. S.","year":"2011","journal-title":"Open Access Emergency Medicine: OAEM"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(97)80144-4"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(95)00192-3"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)23168-8"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.05.006"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1995.tb04412.x"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.050930"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00107.x"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.58.3.432"},{"key":"e_1_2_9_44_1","first-page":"181","article-title":"Paracetamol Overdose in Man: Relationship Between Pattern of Urinary Metabolites and Severity of Liver Damage","volume":"45","author":"Davis M.","year":"1976","journal-title":"Quarterly Journal of Medicine"}],"container-title":["CPT: Pharmacometrics &amp; Systems Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.70045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T04:48:45Z","timestamp":1752468525000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/psp4.70045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1002\/psp4.70045"],"URL":"https:\/\/doi.org\/10.1002\/psp4.70045","archive":["Portico"],"relation":{},"ISSN":["2163-8306","2163-8306"],"issn-type":[{"type":"print","value":"2163-8306"},{"type":"electronic","value":"2163-8306"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"2025-02-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}